Novartis' $4.5 Billion Offer for Full Control Is 'Inadequate,' Chiron Says

Drug Industry Daily
KEYWORDS FDA / Industry
A A

Chiron has rejected Novartis’ recent offer to acquire the biopharmaceutical company, saying the $40 per share cash offer from its largest stockholder is “inadequate.”

To View This Article:

Login

Subscribe To Drug Industry Daily